All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) in combination with PDR001.
Solid Tumors and Lymphomas
Active, not recruiting
Aug 05, 2020
Sep 08, 2017
Sep 30, 2020
18 Years and older (Adult, Older Adult)
MIW 815 (ADU-S100) is a STING agonist
PDR001 is an anti-PD-1 antibody
ECOG ≤ 1 Willing to undergo tumor biopsies from injected and distal lesions
Must have two biopsy accessible lesions:
Symptomatic or untreated leptomeningeal disease. Presence of symptomatic central nervous system metastases Impaired cardiac function or clinically significant cardiac disease Active autoimmune disease or a documented history of autoimmune disease, except vitiligo or resolved childhood asthma/atopy.
Active infection requiring systemic antibiotic therapy. Known history of human immunodeficiency virus infection. Active Epstein-Barr virus, hepatitis B virus or hepatitis C virus Malignant disease, other than that being treated in this study